98%
921
2 minutes
20
In 2001, the Centers for Medicare and Medicaid Services established the New Technology Add-On Payment (NTAP) program to incentivize access to costly new technologies for Medicare beneficiaries. These technologies, authorized by the Food and Drug Administration (FDA), must demonstrate "substantial clinical improvement" when compared to existing technologies. However, in FY2021, the FDA introduced two expedited authorization pathways, allowing technologies with either designation to bypass the "substantial clinical improvement" criterion. We describe the services and payments associated with NTAPs following this policy change.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736715 | PMC |
http://dx.doi.org/10.1093/haschl/qxae182 | DOI Listing |
Diabetologia
September 2025
Department of Diabetology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
This review article, developed by the EASD Global Council, addresses the growing global challenges in diabetes research and care, highlighting the rising prevalence of diabetes, the increasing complexity of its management and the need for a coordinated international response. With regard to research, disparities in funding and infrastructure between high-income countries and low- and middle-income countries (LMICs) are discussed. The under-representation of LMIC populations in clinical trials, challenges in conducting large-scale research projects, and the ethical and legal complexities of artificial intelligence integration are also considered as specific issues.
View Article and Find Full Text PDFClin Res Cardiol
September 2025
Department of Cardiology, University Heart Center, University Hospital Zurich, Center for Translational and Experimental Cardiology (CTEC), University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Background: Diabetic patients with ST-segment elevation myocardial infarction (STEMI) are at an increased risk of cardiovascular events as compared to non-diabetic patients. This analysis investigated outcomes of diabetic patients presenting with multivessel disease (MVD) and STEMI in a contemporary trial and the relevance of an immediate versus staged multivessel PCI strategy in this high-risk population.
Methods: Patients enrolled in the MULTISTARS AMI trial were stratified according to the presence/absence of diabetes.
Cochrane Database Syst Rev
September 2025
Cochrane Evidence Synthesis Unit Germany/UK - Sub-Unit Düsseldorf, Institute of General Practice, Centre for Health and Society, Medical Faculty of the Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Background: In order to improve the outcomes of children and adolescents with type 1 diabetes mellitus (T1DM), access to and quality of comprehensive acute and chronic care services in low- and middle-income countries (LMIC) must be improved.
Objectives: To identify and summarise the characteristics of models of care for T1DM in children and adolescents in LMIC.
Search Methods: We searched MEDLINE, Scopus, the Cochrane Central Register of Controlled Trials (CENTRAL), and the World Health Organization (WHO) Global Index Medicus from inception to 11 December 2023 without restrictions.
ERJ Open Res
September 2025
Department of Respiratory Diseases, Bichat-Claude Bernard Hospital, Paris, France.
https://bit.ly/4bY6LMc.
View Article and Find Full Text PDFRisk Manag Healthc Policy
September 2025
Center for Geriatric Healthcare Services and Health Education, Rizhao, People's Republic of China.
Background: Older adults in rural China bear a significant proportion of their healthcare expenses through out-of-pocket payments, resulting in a considerable financial burden on their families.
Objective: This study aimed to explore the key factors influencing adult children's involvement in financing healthcare expenses for their elderly parents in rural China.
Methods: Data were collected by in-depth interviews using a semi-structured interview guide approved by all researchers.